Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer - Hardcover

Über die Autorin bzw. den Autor

RAYMOND M. REILLY is a Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He has more than twenty years of experience in the field of radiolabeled antibody and peptide targeting of cancer. Dr. Reilly has written over 180 publications in the field, including more than 100 scientific papers on radiopharmaceuticals for cancer imaging and targeted radiotherapy.

Von der hinteren Coverseite

The essential, up-to-date guide to fighting cancer with targeted radiotherapy

Continuing to gain momentum as a novel treatment strategy, targeted radiotherapy relies on and exploits the characteristics of malignant cells to attack tumors with radiation. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this exciting radiopharmaceutical field with up-to-date developments and step-by-step discussion covering a range of diverse topics, including optimization in the design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from pivotal clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. Unique aspects of the book include:

• A translational focus on development, preclinical, and clinical evaluation of novel targeted radiopharmaceuticals for treating cancer

• A discussion on health economics issues that have an impact on the ultimate use of targeted radiotherapy in clinical oncology

• A broad discussion of the utility of targeted radiotherapy for multiple tumor types

• New and emerging areas like molecular imaging, the bystander effect, and combining targeted radiotherapy with cytolytic virus therapy of tumors

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer enlists internationally renowned experts and emerging leaders in the field who explain the groundbreaking science that has delivered a wealth of new findings and is defining the role of this new cancer treatment in the future. Review of the current state of the art provides provocative insight from today's cancer researchers as they reach for tomorrow's cures.

Aus dem Klappentext

The essential, up-to-date guide to fighting cancer with targeted radiotherapy

Continuing to gain momentum as a novel treatment strategy, targeted radiotherapy relies on and exploits the characteristics of malignant cells to attack tumors with radiation. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this exciting radiopharmaceutical field with up-to-date developments and step-by-step discussion covering a range of diverse topics, including optimization in the design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from pivotal clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. Unique aspects of the book include:

• A translational focus on development, preclinical, and clinical evaluation of novel targeted radiopharmaceuticals for treating cancer

• A discussion on health economics issues that have an impact on the ultimate use of targeted radiotherapy in clinical oncology

• A broad discussion of the utility of targeted radiotherapy for multiple tumor types

• New and emerging areas like molecular imaging, the bystander effect, and combining targeted radiotherapy with cytolytic virus therapy of tumors

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer enlists internationally renowned experts and emerging leaders in the field who explain the groundbreaking science that has delivered a wealth of new findings and is defining the role of this new cancer treatment in the future. Review of the current state of the art provides provocative insight from today's cancer researchers as they reach for tomorrow's cures.